Alkem Laboratories Announces Q2 FY26 Results: Revenue Up 17%, EBITDA Up 22%
Alkem Laboratories announced its Q2 FY26 results with a 17% increase in revenue and a 22% increase in EBITDA. CEO Dr. Vikas Gupta highlighted robust growth across key markets and seamless adaptation to GST revisions.
The financial results indicate a positive trend for the company, which could be of interest to investors.
The announcement highlights positive financial results, including revenue and EBITDA growth, and positive comments from the CEO.
* Alkem Laboratories Limited announced its standalone and consolidated financial results for the quarter ended 30th September 2025. * The Board of Directors approved the results on 13th November 2025. * Q2 FY26 saw robust growth across India, the US, and key international markets, with healthy traction in new product launches. * The company has transferred Generic Business Undertaking to Alkem Wellness Limited w.e.f 1st October 2025 * Dr. Vikas Gupta, CEO of Alkem, commented on the GST revision as a positive step, ensuring a seamless transition and contributing to a stronger EBITDA profile.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.